UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2021

The second calendar quarter (2Q) of 2021 financial results were dramatically different from 2Q 2020 because 2Q 2020 results were the low point of Utah Medical Products, Inc.’s (Nasdaq: UTMD) performance during the COVID-19 pandemic, during a time when there were restrictions on so-called nonessential medical procedures. Therefore, UTMD management reports quarterly income statement results compared to the same periods not only in 2021 compared to 2020, but also compared to 2019. The Company’s stated objective in 2021 has been to try to fully recover back to its 2019 financial performance. Please see the income statements for all three years on the last page.  […]

Read More

CenExel Clinical Research Acquires ForCare Clinical Research

CenExel Clinical Research, Inc., (“CenExel”) announces the acquisition of ForCare Clinical Research (“CenExel FCR”), a Tampa-based clinical research organization with Principal Investigators who have more than 40 years of combined research experience. CenExel FCR conducts Phase I through Phase IV studies in both chronic and acute conditions, primarily in Dermatology […]

Read More

BIOMERICS ANNOUNCES ACQUISITION OF BERG MANUFACTURING INC. & KNIGHT MACHINING LLC.

Biomerics LLC, a leading mid-market contract manufacturer for the interventional medical device market, announced it has acquired a majority interest in Berg Manufacturing Inc. Berg Manufacturing, based in Santa Clara, California, is an industry leader in Swiss micromachining for the advanced robotic surgery, endoscope, and interventional catheter markets. […]

Read More

Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries

Advancing its mission to expand access to genetic testing, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today launched a new version of its market-leading MyRisk Hereditary Cancer Test. For the first time, women of all ancestries can now receive a personalized polygenic breast cancer risk assessment together with the market’s most accurate hereditary cancer test. […]

Read More

BioUtah Statement on Launch of Altitude Lab’s Investor Coalition to Fund and Mentor Utah’s Life Sciences Startups

Salt Lake City – BioUtah President and CEO, Kelvyn Cullimore, issued the following statement upon the launch of Altitude Lab’s Investor Coalition to fund and mentor life sciences startups in Utah. BioUtah President and CEO, Kelvyn Cullimore, issued the following statement upon the launch of Altitude Lab’s Investor Coalition to fund and mentor life sciences […]

Read More

The University of Utah and RenalytixAI Partner to Drive Innovation in Kidney Health

Utah’s RenalytixAI and the University of Utah last week announced a partnership to improve kidney health and reduce the risk of kidney failure for large scale populations in the earliest stages of kidney disease. The partnership intends to implement RenalytixAI’s in vitro diagnostic platform, KidneyIntelX, in combination with a range of advanced clinical management solutions […]

Read More

Co-Diagnostics JV CoSara Receives Clearance from Indian FDA for COVID-19 2-Gene Multiplex Test

Co-Diagnostics announced November 25 that CoSara Diagnostics Pvt Ltd (“CoSara,” or the “JV”), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization (“CDSCO”) in India to manufacture and sell its Saragene™ COVID-19 2-gene multiplex RT-PCR test. Dwight Egan, CEO of Co-Diagnostics, said “tests built on […]

Read More

IDbyDNA and Illumina Launch New Rapid Test to Better Detect COVID-19, Flu, Respiratory Co-Infections

Utah-based IDbyDNA announced yesterday that, in an effort to help labs better identify respiratory pathogens and avoid overuse of antimicrobial drugs, IDbyDNA and Illumina, Inc. are co-launching the new Respiratory Pathogen ID/AMR Target Enrichment Assay. The test, currently for research use only, will improve testing for infectious diseases, including COVID-19, and will leverage IDbyDNA’s Explify® […]

Read More